DHHS/PHS/FDA/Office Of Facilities, Acquisition, And Central Services, Division of Contracts and Program Management, HFA-512(COB), 5600 Fishers Lane, Rockville, MD 20857

A -- DEVELOPMENT OF ANIMAL MODEL AND IN VITRO ASSAYS FOR THE IMMUNOTOXICITY RISK ASSESSMENT. SOL 267839-00-99 DUE 021999 POC Trudy Dartouzos, Contract Specialist, ph: 301/827-7165, fax: 301/827-7103 See note #1. The FDA, Center for Devices and Radiological Health [CDRH] intends to award a purchase order for 960 hours of technical support including animal treatment and in vitro bioassays aimed to define humoral and cellular factors involved in Type I hypersensitivity. This will involve measurement of proliferative capacity of immune cells and antibody analysis. Specifc tasks to be performed under GLP guidelines are: 1] perform proliferation assay with spleen and lymph node cells, 2] perform the ELISA assay to determine specific anti latex IgE antibodies, 3] perform electrophoreses and characterization of anti latex IgE antibodies using Western blots, and 4] prepare final report. Work to be completed by January 31, 2000. Written quotes due by 2/19/99. Posted 02/02/99 (W-SN293518). (0033)

Loren Data Corp. http://www.ld.com (SYN# 0006 19990204\A-0006.SOL)